中文摘要：

决定 Xinfeng 囊的有效性和安全的目的(， XFC ) 为风湿性关节炎(RA ) 的治疗有减少的肺的功能的病人。这是 80 个 RA 病人的使随机化的控制临床的试用的方法。参加者被块随机化分到试用组(40 个盒子) 和控制组(40 个盒子) 。试用组与 XFC 被对待，每次，三每天预定 2 个月的三片药片。控制组与 tripterygium glycoside (TPT ) 被对待，每次，三每天预定 2 个月的二片药片。两个组被跟随在上面在 2 个月以后。临床的效果，在联合、肺的功能的变化，和在治疗前后的生活的质量被观察；安全索引也被评估。结果伤害，胀大，关节的早上僵硬的温柔，和持续时间显然与基线相比在试用和控制组在治疗以后被减少(P < 0.01 ) 。与以前相比治疗，手掌握力量在试用组(P=0.0000 ) 在治疗以后显著地增加了；肺的函数参数象在终止 / 力量的第一秒的强迫的吐气的体积那样重要能力(FEV ₁/FVC), 强迫的重要能力的 50% 吐气的流动(FEF ₅₀), 碳一氧化物扩散能力(DLco ) 被增加(P < 0.01 或 P < 0.05 ) ；生活例如的质量的措施角色物理，身体疼痛，活力和心理健康也在试用组在治疗以后被改进(所有 P < 0.05 ) 。在试用组的联合胀大与控制组(P=0.0043 ) 相比减少了，当手掌握力量在处理(P=0.0000 ) 以后被增加时。FEF ₅₀, DLco 的增加，和象活力和心理健康那样的生活的质量的尺寸都比控制组在试用组是显著地更大的(P < 0.05 或 P < 0.01 ) 。结论 XFC 不仅在 RA 病人减轻了联合疼痛，而且显著地改进了通风和肺的散开功能。因此， XFC 能改进整个身体功能并且提高 RA 病人的生活的质量。

英文摘要：

Objective： To determine the effectiveness and safety of Xinfeng Capsules （新风胶囊, XFC） for the treatment of rheumatoid arthritis （RA） patients with decreased pulmonary function. Methods： This was a randomized controlled clinical trial of 80 RA patients. Participants were assigned to the tdal group （40 cases） and the control group （40 cases） by block randomization. The trial group was treated with XFC, three pills each time three times daily for 2 months. The control group was treated with tripterygium glycoside （TPT）, two pills each time three times daily for 2 months. Both groups were followed up after 2 months. The clinical effects, changes in joint and pulmonary function, and quality of life before and after treatment were observed; safety indices were also evaluated. Results： Pain, swelling, tenderness, and duration of morning stiffness of joints were obviously decreased after treatment in both the trial and the control groups compared with baseline （P〈0.01）. Compared with before treatment, hand grip strength increased significantly after treatment in the trial group （P=0.0000）; pulmonary function parameters such as forced expiratory volume in the first second of expiration/forced vital capacity （FEV1/FVC）, 50% of the expiratory flow of forced vital capacity （FEFso）, carbon monoxide diffusing capacity （DLco） were increased （P〈0.01 or P〈0.05）; measures of quality of life such as role-physical, body pain, vitality and mental health were also improved after treatment in the trial group （all P〈0.05）. Joint swelling in the trial group decreased compared with the control group （P=0.0043）, while hand grip strength was increased after treatment （P=0.0000）. The increase in FEFs0, DLco, and the dimensions of quality of life such as vitality and mental health were all significantly greater in the trial group than the control group （P〈0.05 or P〈0.01）. Conclusions： XFC not only relieved joint pain in RA patients, but also significantly i